28522288|t|Grade Group Underestimation in Prostate Biopsy: Predictive Factors and Outcomes in Candidates for Active Surveillance
28522288|a|We intended to analyze the outcomes and predictive factors for underestimating the prostate cancer (PCa) grade group (GG) from prostate biopsies in a large monocentric cohort of patients treated by minimally invasive radical prostatectomy (RP). Using a monocentric prospectively maintained database, we included 3062 patients who underwent minimally invasive RP between 2006 and 2013. We explored clinicopathologic features and outcomes associated with a GG upgrade from biopsy to RP. Multivariate logistic regression was used to develop and validate a nomogram to predict upgrading for GG1. Biopsy GG was upgraded after RP in 51.5% of cases. Patients upgraded from GG1 to GG2 or GG3 after RP had a longer time to biochemical recurrence than those with GG2 or GG3 respectively, on both biopsy and RP, but a shorter time to biochemical recurrence than those who remained GG1 after RP (P < .0001). In multivariate analyses, variables predicting upgrading for GG1 PCa were age (P = .0014), abnormal digital rectal examination (P < .0001), prostate -specific antigen density (P < .0001), percentage of positive cores (P < .0001), and body mass index (P = .037). A nomogram was generated and validated internally. Biopsy grading system is misleading in approximately 50% of cases. Upgrading GG from biopsy to RP may have consequences on clinical outcomes. A nomogram using clinicopathologic features could aid the probability of needing to upgrade GG1 patients at their initial evaluation.
28522288	0	11	Grade Group	T170	UMLS:C0008902
28522288	12	27	Underestimation	T033	UMLS:C0243095
28522288	31	46	Prostate Biopsy	T058	UMLS:C0194804
28522288	48	66	Predictive Factors	T170	UMLS:C0683956
28522288	71	79	Outcomes	T033	UMLS:C1518681
28522288	83	93	Candidates	T098	UMLS:C1257890
28522288	98	117	Active Surveillance	T058	UMLS:C1827061
28522288	145	153	outcomes	T033	UMLS:C1518681
28522288	158	176	predictive factors	T170	UMLS:C0683956
28522288	201	216	prostate cancer	T038	UMLS:C0376358
28522288	218	221	PCa	T038	UMLS:C0376358
28522288	223	234	grade group	T170	UMLS:C0008902
28522288	236	238	GG	T170	UMLS:C0008902
28522288	245	262	prostate biopsies	T058	UMLS:C0194804
28522288	274	292	monocentric cohort	T098	UMLS:C0599755
28522288	316	356	minimally invasive radical prostatectomy	T058	UMLS:C0194810
28522288	358	360	RP	T058	UMLS:C0194810
28522288	371	416	monocentric prospectively maintained database	T170	UMLS:C0242356
28522288	458	479	minimally invasive RP	T058	UMLS:C0194810
28522288	546	554	outcomes	T033	UMLS:C1518681
28522288	573	575	GG	T170	UMLS:C0008902
28522288	589	595	biopsy	T058	UMLS:C0005558
28522288	599	601	RP	T058	UMLS:C0194810
28522288	603	635	Multivariate logistic regression	T062	UMLS:C0206031
28522288	671	679	nomogram	T170	UMLS:C1450294
28522288	705	708	GG1	T170	UMLS:C0008902
28522288	710	716	Biopsy	T058	UMLS:C0005558
28522288	717	719	GG	T170	UMLS:C0008902
28522288	739	741	RP	T058	UMLS:C0194810
28522288	784	787	GG1	T170	UMLS:C0008902
28522288	791	794	GG2	T170	UMLS:C0008902
28522288	798	801	GG3	T170	UMLS:C0008902
28522288	808	810	RP	T058	UMLS:C0194810
28522288	832	854	biochemical recurrence	T033	UMLS:C2985506
28522288	871	874	GG2	T170	UMLS:C0008902
28522288	878	881	GG3	T170	UMLS:C0008902
28522288	904	910	biopsy	T058	UMLS:C0005558
28522288	915	917	RP	T058	UMLS:C0194810
28522288	941	963	biochemical recurrence	T033	UMLS:C2985506
28522288	988	991	GG1	T170	UMLS:C0008902
28522288	1075	1078	GG1	T170	UMLS:C0008902
28522288	1079	1082	PCa	T038	UMLS:C0376358
28522288	1105	1140	abnormal digital rectal examination	T058	UMLS:C1384593
28522288	1154	1162	prostate	T017	UMLS:C0033572
28522288	1154	1188	prostate -specific antigen density	T033	UMLS:C0243095
28522288	1202	1230	percentage of positive cores	T033	UMLS:C0243095
28522288	1248	1263	body mass index	T170	UMLS:C4055400
28522288	1278	1286	nomogram	T170	UMLS:C1450294
28522288	1327	1333	Biopsy	T058	UMLS:C0005558
28522288	1334	1348	grading system	T058	UMLS:C1273712
28522288	1404	1406	GG	T170	UMLS:C0008902
28522288	1412	1418	biopsy	T058	UMLS:C0005558
28522288	1422	1424	RP	T058	UMLS:C0194810
28522288	1450	1467	clinical outcomes	T033	UMLS:C1518681
28522288	1471	1479	nomogram	T170	UMLS:C1450294
28522288	1561	1564	GG1	T170	UMLS:C0008902
28522288	1591	1601	evaluation	T058	UMLS:C0220825